Originally published by our sister publication Specialty Pharmacy Continuum
Amneal Pharmaceuticals has launched exenatide 1.2 and 2.4 mL prefilled pen injection, an AP-rated generic equivalent for Byetta (Amylin Pharmaceuticals). Exenatide is a glucagon-like peptide-1 (GLP-1) agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Availability of this generic alternative is significant as the brand was recently discontinued.1 Prescribers and patients now have access to exenatide therapy again.
Both the 5-mcg (1.2 mL) and 10-mcg (2.4 mL) sized pens deliver 60 subcutaneous doses. Needles are not included, and pens should be stored in the refrigerator until first use, at which time they can be kept at room temperature not to exceed 77° F. A website featuring instructions for use and other information is live at AmnealExenatide.com.
Patients have experienced changes in kidney function, low blood sugar and inflammation of the pancreas while using exenatide. The most common side effects include nausea, low blood sugar, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, constipation and weakness. For complete prescribing information, refer to the package insert available here.
Exenatide injection is available for sale now through most wholesalers.
1 Byetta was not discontinued due to safety or efficacy reasons.
